GSK, HGS lupus drug wins green light in Europe
Monday, May 23, 2011
(Reuters) - The first new treatment for lupus in a half-century was recommended for approval in Europe on Friday, offering a new option for patients and underpinning multibillion-dollar sales expectations for its makers.
The companies said the European Medicines Agency had backed use of Benlysta, discovered by Human Genome Sciences and developed with GlaxoSmithKline, to combat the disease that causes the immune system to attack joints and organs.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms